GSK 2881078

Drug Profile

GSK 2881078

Alternative Names: GSK-2881078

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cachexia

Most Recent Events

  • 02 Dec 2017 GlaxoSmithKline plans a phase II trial for Cachexia in February 2018 , (NCT03359473)
  • 01 Apr 2017 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Cachexia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 01 Dec 2016 GlaxoSmithKline completes a phase I trial for Cachexia (In volunteers) in USA (NCT02567773)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top